MG 129 Uracil, [2-13C, 1,3-15N2]- |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC Chromatogram |
|
| Solid | |
| 1 mg $615 | |
| Screw cap v-vial | 5 mg $1930 |
| M.W. 115.1 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MC 281 Uracil, [14C(U)] Click here for Typical Certificate of Analysis |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC radiochromatogram |
|
| Ethanol:water (2:98) solution, 100 µCi/ml | |
| > 180 mCi(6.66-8.14 GBq)/mmol | 10 µCi (370 kBq) $1240 |
| NextGen V-Vial | 50 µCi (1.85 MBq) $3970 |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MC 124 Uracil, [2-14C]- Click here for Typical Certificate of Analysis |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 100 µCi/ml | 50 µCi (1.85 MBq) $3970 |
| > 50 mCi(1.85 GBq)/mmol | 250 µCi (9.25 MBq) $4260 |
| NextGen V-Vial | 1 mCi (37 MBq) $6345 |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MC 159 Uracil, [6-14C]- Click here for Typical Certificate of Analysis |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 100 µCi/ml | 50 µCi (1.85 MBq) $3970 |
| > 50 mCi(1.85 GBq)/mmol | 250 µCi (9.25 MBq) $5125 |
| NextGen V-Vial | |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 610 Uracil, [5-3H]- Click here for Typical Certificate of Analysis |
|
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 1 mCi/ml | 50 μCi (1.85 MBq) $1160 |
| > 10 Ci(370 GBq)/mmol | 250 μCi (9.25 MBq) $1970 |
| NextGen V-Vial | |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 610M Uracil, [5-3H]- |
|
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 1 mCi/ml | 50 μCi (1.85 MBq) $1160 |
| > 5 Ci(185 GBq)/mmol | 250 μCi (9.25 MBq) $1970 |
| NextGen V-Vial | |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 512 Uracil, [5,6-3H]- |
|
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 1 mCi/ml | |
| > 40 Ci(1.48 TBq)/mmol | 250 µCi (9.25 MBq) $1970 |
| NextGen V-Vial | 1 mCi (37 MBq) $2245 |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 512L Uracil, [5,6-3H]- |
|
| Click here for Typical Certificate of Analysis | |
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 1 mCi/ml | |
| 10-39 Ci(0.37-1.443 TBq)/mmol | 250 µCi (9.25 MBq) $1970 |
| NextGen V-Vial | 1 mCi (37 MBq) $2245 |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 656 Uracil, [6-3H]- Click here for Typical Certificate of Analysis |
|
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Aqueous solution, 1 mCi/ml | 250 µCi (9.25 MBq) $1970 |
| > 10 Ci(0.37 TBq)/mmol | 1 mCi (37 MBq) $2130 |
| NextGen V-Vial | 5 mCi (185 MBq) $2825 |
| M.W. 112.09 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
